Option Care Health (OPCH) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Option Care Health

NasdaqGS•Healthcare•Medical Care Facilities

$24.47+0.95(0.04%)Pre-market

Market Cap

$3.72B

P/E

17.7x

P/S

0.7x

P/B

2.9x

Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapy and services; home infusion services to treat heart failure; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as Duchenne muscular dystrophy, multiple sclerosis, Alzheimer's disease, and other neurological disorder; infusion therapies for bleeding disorders, such as hemophilia and von Willebrand diseases; therapies for women with high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. The company markets its services through patient referrals, including physicians, hospital discharge planners, hospital personnel, health maintenance organizations, and preferred provider organizations. The company is headquartered in Bannockburn, Illinois.

How this company scores

GoodMetricSide Score: 68/100

Strongest: Cash & Earnings Quality (23/25); weakest: Balance Sheet & Red Flags (15/25).

Profitability15/25

Growth15/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality23/25

Strengths

Rising free cash flowHigh ROECash-backed earningsConsistent growth

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 17.7x5y range 17.7x – 53.3x

Currently below its 20-quarter median.

P/S · 0.7x5y range 0.7x – 1.5x

Currently below its 20-quarter median.

P/B · 2.9x5y range 2.7x – 4.3x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

Some Concerns

Margin Pressure

Watch

Operating margins declined 7.6% — watch for continued compression, which may signal competitive or cost pressure.

Earnings Quality

Watch

FCF/Net Income has dropped below 0.7x in 4 quarters — monitor for earnings quality deterioration.

Price & Volume

Market Cap $3.72B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $5.69B
Q. Revenue: $1.44B
TTM EBITDA: $401.60M
TTM Op. Income: $333.69M
Q. Op. Income: $85.14M
TTM Net Income: $209.58M
Q. Net Income: $53.91M
EPS: $0.35
Shares Out.: $152.93M

$5.69B in TTM revenue grew 7.7% YoY, reaching $1.44B last quarter. TTM EBITDA of $401.60M and TTM operating income of $333.69M show growth is flowing through to the bottom line. TTM net income of $209.58M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 18.5%
EBITDA Margin: 7.1%
Op. Margin: 5.9%
Net Margin: 3.7%

Op. margin of 5.9% is up 0.1% YoY — cost efficiency is improving. Net margin at 3.7% and gross margin of 18.5% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 1% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 17.7x
P/S Ratio: 0.7x
P/B Ratio: 2.9x

At 17.7x P/E, the stock trades within typical market levels. P/S of 0.7x and P/B of 2.9x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Across the last 8 quarters, P/E has fallen for 2 consecutive quarters — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $3.38B
Cash: $193.77M
Long-Term Debt: $1.15B
Book Value: $1.26B
D/E Ratio: 0.9
Debt/EBITDA: 11.2

With $3.38B in assets and $1.15B in long-term debt, D/E is 0.9and book value is $1.26B — a conservative capital structure with a cushion to weather downturns. Over the past year, debt/equity is up 13% — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $183.59M
TTM Free Cash Flow: $303.85M
FCF Margin: 5.3%
FCF / Net Income: 1.4

TTM FCF of $303.85M on $183.59M in operating cash flow. The FCF / Net Income ratio of 1.4x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 26% — an improving trend.